

1 **Factors associated with the uptake of Intermittent Preventive Treatment (IPTp-SP) for**
2 **malaria in pregnancy: further analysis of the 2018 Nigeria Demographic and Health Survey.**

3 Godwin Okeke Kalu^{1*}, Joel M Francis^{2¶}, Latifat Ibisomi^{1,3}, Tobias Chirwa¹, Juliana Kagura^{1¶}

4 ¹School of Public Health, Faculty of Health Sciences, University of the Witwatersrand,
5 Johannesburg, Gauteng, South Africa

6 ²Department of Family Medicine and Primary care, School of Clinical Science, Faculty of Health
7 Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

8 ³Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria

9 *Corresponding author

10 Email: chinwemerikalu@gmail.com (GOK)

11 ¶These authors contributed equally to this work

12

13

14

15

16

17

18 **Abstract**

19 Pregnancy-associated malaria is preventable and curable with intermittent preventive treatment
20 with Sulfadoxine-Pyrimethamine (IPTp-SP). However, despite the effectiveness of IPTp-SP
21 against malaria in pregnancy, the uptake among pregnant women in Nigeria remains very low.
22 Thus, this study aimed to establish the factors associated with the uptake of at least one dose and
23 optimal doses of IPTp-SP among pregnant women aged 15 to 49 years living in Nigeria in 2018.
24 The study included 12,742 women aged 15 to 49 years with live births two years before or during
25 the 2018 Nigeria Demographic Health Survey (NDHS) in the analysis. Descriptive analysis was
26 carried out to determine the prevalence of IPTp-SP uptake. Multivariable logistic regression was
27 used to establish the factors associated with receiving IPTp-SP during pregnancy, adjusting for
28 possible confounding factors. Given the complex survey design, all analyses adjusted for sampling
29 weight, stratification and clustering. The p-value of <0.05 was considered significant. In 2018,
30 the prevalence of at least one dose of IPTp-SP was 63.6% (95% CI:62.0–65.1), and optimal doses
31 of IPTp-SP were 16.8% (95% CI:15.8–17.8) during pregnancy. After the multivariable analysis,
32 age group, region, frequency of ANC visits, belief in IPTp-SP effectiveness, and morbidity caused
33 by malaria predicted the uptake of at least one IPTp-SP dose. Similar maternal characteristics,
34 including household wealth index, spouse's educational level and media exposure, were
35 significantly associated with taking optimal IPTp-SP doses. For instance, women in the wealthiest
36 households whose husbands had secondary education predicted a four-fold increase in uptake of
37 at least one IPTp-SP dose (aOR:4.17; 95% CI:1.11–8.85).

38 The low prevalence and regional variations of IPTp-SP uptake in the study area imply that most
39 pregnant women in Nigeria are at substantial risk of pregnancy-associated malaria. Therefore,

40 stakeholders should explore context-specific strategies to improve the IPTp-SP coverage across
41 the regions in Nigeria.

42 **Keywords:** Pregnancy-associated malaria, Intermittent preventive treatment, Sulfadoxine-
43 Pyrimethamine, Antenatal care, Malaria morbidity, Nigeria

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64 **Introduction**

65 Over the past two decades, about 1.7 billion malaria cases and 10.6 million malaria-related deaths
66 were averted (1). Also, malaria mortality rates, that is, deaths per 100,000 population at risk,
67 declined from 25 in 2000 to 12 in 2015 and 10 in 2019, globally (2). Equally, the estimated number
68 of deaths decreased from 896,000 in 2000 to 558,000 in 2019 (2,3). However, , in 2020, malaria
69 deaths increased to 627,000, partially due to disruptions of malaria services during the COVID-19
70 pandemic. In 2020, the WHO African region accounted for 95% of the 241 million cases and 94%
71 of the global malaria deaths with four countries accounting for almost half of the global malaria
72 deaths (2). These four countries are Nigeria (31.9%), the Democratic Republic of the Congo
73 (13.2%), United Republic of Tanzania (4.1%), and Mozambique (3.8%) (2). Nonetheless, young
74 children and pregnant women remain at significant risk of malaria infections. In 2019, 35% (12
75 million) of the estimated 33 million pregnant women living across 33 countries in the WHO
76 African region were exposed to malaria infections during pregnancy (2). In the same year, the
77 exposure to malaria infections during pregnancies resulted to 822,000 children born with low
78 birthweight in these 33 countries (2)

79 In addition, approximately 50 million pregnant women remains at significant risk of pregnancy-
80 associated malaria and possible malaria-related death annually (4). The risk associated with
81 malaria in pregnancy can be drastically reduced by using Intermittent Preventive Treatment with
82 Sulphadoxine-Pyrimethamine (IPTp-SP) for pregnancy-associated malaria as part of a multilevel
83 three-staged approach (5). IPTp-SP utilisation among pregnant women has contributed to nearly
84 42% decrease in low birth weight, 38% decrease in neonatal death, and 65% decrease in placental
85 malaria in SSA countries (1,6). However, full benefits are evident when pregnant women receive
86 three or more IPTp-SP doses (6). Receiving optimal IPTp-SP doses during pregnancy has

87 increased the mean birth weight, reduced low birth weight, and fewer placental malaria than taking
88 most two doses (6). The WHO revised IPTp-SP guidelines in 2012 to increase the number of
89 Sulphadoxine-Pyrimethamine (SP) doses taken by pregnant women (5). Prior to 2012, the policy
90 proposed that IPTp-SP should be given to pregnant women at every ANC visit to ensure they
91 receive at least two SP doses whereas the revised policy recommends all pregnant women should
92 receive one SP dose at every scheduled ANC visit except during first trimester at a one-month
93 interval between each SP dose until time of delivery (5). Nigeria adopted the new IPTp-SP
94 guideline in 2014 for preventing or treating malaria or asymptomatic malaria infection during
95 pregnancy (7).

96 Despite the efforts by the WHO to increase the coverage of IPTp-SP in sub-Saharan African
97 countries, several maternal characteristics have been established as a barrier to IPTp-SP uptake
98 during pregnancy. Studies have reported that pregnant women's attitudes and motivation to receive
99 IPTp-SP was related to their levels of knowledge of malaria-related factors such as morbidities
100 caused by malaria (8,9). Similarly, region, religion, age, and marital status influenced the number
101 IPTp-SP doses received during pregnancy (8,10,11). Socioeconomic considerations including
102 education level, spouse's education level, employment status, health insurance coverage and
103 household wealth index influenced IPTp-SP uptake (12,13). Increased uptake during pregnancy
104 was associated with higher education (14,15), and some studies found a strong association between
105 being employed and IPTp-SP uptake (16). Also, several studies established that IPTp-SP uptake
106 was pro-rich, such that women in the "middle" to "richest" household wealth index had higher
107 IPTp-SP uptake compared to those in the "poorest" to "poorer" wealth categories, including uptake
108 of at least three IPTp-SP doses during pregnancy (10,11,17,18).

109 The prevalence of at least one SP dose in Nigeria has increased from 27% in 2013 to 51% in 2015
110 and about 64% in 2018 (19). However, despite the relatively high prevalence of taking at least one
111 dose of SP by pregnant women in Nigeria , the gap between uptake of the first dose of the
112 antimalaria drug and at least three doses remains significantly large . For example, in 2018, the
113 prevalence of at least one dose was 64% compared to the about 17% prevalence of three or more
114 IPTp-SP doses (optimal doses) (19). This study examines the prevalence of IPTp-SP among
115 pregnant women and factors associated with the uptake of at least one dose and three or more doses
116 of IPTp-SP using the 2018 Nigeria Demographic Health Survey (NDHS).

117

118

119

120

121

122

123

124

125

126

127 **Methods**

128 **Study design and study setting**

129 The primary study; the Nigeria Demographic Health Survey women's data, was a cross-sectional
130 study conducted to provide estimates of the Nigerian populace's basic demographic and health
131 indicators. The survey included samples from 36 States, including the Federal Territory Capital
132 (FCT). The sampling frame of the NDHS relied on the National Population and Housing Census
133 (NPHC) carried out in 2006. Two sampling stages were carried out, and each of the 36 states and
134 the Federal Capital Territory (FCT) were grouped into urban and rural areas to form 74 strata (19).
135 First, 1389 census enumeration areas (EAs) were chosen from 74 strata using probability
136 proportional to EA size as clusters independently. Secondly, 30 households were randomly
137 selected without replacement from each cluster to form a sample size of 41,666 households.
138 Weighting accurately represented the population during the NDHS dataset analysis due to the
139 unequal distributed samples across each state and the potential disparity in the response rates. A
140 total of 42,121 women, 15 to 49 years old, was scheduled for an interview, and 41,821 women
141 were successfully interviewed (99% response rate). All women of childbearing age, between 15 to
142 49 years old, either resident in the selected household or female guests available in the households
143 a night before 14 August to 29 December 2018, were eligible and interviewed. A detailed
144 methodology for the 2018 NDHS has been published elsewhere (19).

145

146

147 **Study population**

148 The study population were all women aged 15 to 49 years who had live births during or two years
149 before the survey resident in Nigeria between 2016 and 2018. This study involved the secondary
150 data analysis of the data obtained from the NDHS Women dataset collected between August to
151 December 2018.

152 **Sampling and sample size**

153 From the survey sampling frame, 41,821 women of childbearing ages (15 to 49 years) were
154 interviewed. Among these women, 12,935 had livebirths during or two years preceding the 2018
155 NDHS. Of these, 12,742 women were extracted who reported to have received and known the
156 exact number of IPTp-SP doses they took during their last pregnancy. These 12,742 women served
157 as the analysis sample for this study after the survey weighting was applied ([Fig 1](#)).

158 **Fig 1: The Flow chart of the sample included in the NDHS 2018**

159
160
161
162
163
164
165
166
167
168
169
170

171 **Study variables**

172 The extraction and coding of variables from the 2018 NDHS women dataset for the analysis were
 173 guided by previous literature (20,21), and presented in [Table 1](#).

174 **Table 1: Categories and operational definitions of selected exposure variables**

Exposure variables	Definitions/Categories
Age in years	Age of the respondent during the 2018 NDHS (15-24, 25-34, 35+)
Marital status	Unmarried (singles and formerly married; widows and divorced) and married, including co-habiting
Household wealth Index	Economic/wealth status of respondents' household (Poorest, poorer, middle class, richer, richest)
Region or Geopolitical zone	This is region or geopolitical zone where a respondent reside in Nigeria (North Central, North East, North West, South East, South South, South West)
Residential areas	This is the area of residence of respondents (urban, rural)
Highest Educational Levels	Respondent's formal level of education (such as; none, primary level, secondary level, higher level)
Employment status	This is respondent's employment status (Not employed, employed)
Spouse's Education Level	This is the formal education level of respondent's spouse or partner (none, primary, secondary, higher level)
Frequency of ANC Visits	This is the number times a respondent visited antenatal care (ANC) clinic during pregnancy (None, less than 4 visits, 4+ visits)
ANC Initiation	The trimester a respondent commenced antimalaria treatment (IPTp-SP) during pregnancy (1st Trimester, 2nd trimester, 3rd trimester)
Number of children born	Total number children even born (Less than four children, four or more children)
Belief in the effectiveness of IPTp-SP	Respondent's belief or trust in the efficacy of IPTp_SP to protect them and their fetus against malaria infection during pregnancy (Low, Average, high)
Belief about Malaria morbidity	Respondent's belief or awareness of the morbidity caused by malaria in pregnancy (Low, Average, High)
Health Insurance Coverage	Respondent who subscribed to any form of health insurance (yes, no)
Exposed to media messages	This was generated from whether a respondent used any of newspaper/magazine, radio or television (yes, no)

175

176 **Outcome variables**

177 The outcome variables are the uptake of at least one dose of IPTp-SP and optimal doses of IPTp-
178 SP during pregnancy. The outcomes were created using responses from the following two NDHS
179 survey questions (19): “*did you take SP/Fansidar to prevent you from getting malaria during*
180 *pregnancy?* and *how many times did you receive SP/Fansidar during this pregnancy?*” For
181 statistical analysis, the uptake of at least one dose of IPTp-SP was categorised and coded into 0
182 = no dose of IPTp-SP and 1 = at least one dose of IPTp-SP (≥ 1 dose). The uptake of optimal doses
183 of IPTp-SP was categorised and coded into 0 = two or fewer doses (≤ 2 doses) and 1 = at least
184 three doses of IPTp-SP (≥ 3 doses) (10,21)

185 **Exposure variables**

186 The extracted exposure variables were sub-grouped into the following factors empirically or
187 theoretically associated with uptake of IPTp-SP: sociodemographic, pregnancy-related, and
188 knowledge of malaria-related factors. Sociodemographic factors include residential areas, age in
189 years, household wealth index, the highest level of education, region, religion, employment and
190 spouse’s educational attainment. Pregnancy-related factors include frequency of ANC visits, the
191 timing of first ANC initiation, and parity. In addition, knowledge of malaria-related factors
192 includes belief in the effectiveness of IPTp-SP, belief about malaria consequences, subscription to
193 health insurance and media exposure. The household wealth index was derived in the primary
194 study (NDHS 2018) by scoring each number and asset owned by the selected households using
195 principal component analysis (PCA). The assets ranged from a television to a bicycle or car and
196 housing characteristics such as the source of drinking water, toilet facilities, and flooring materials.
197 Then, the National wealth quintiles or index compiled by allocating the household score to each

198 usual (de jure) household resident. Subsequently, each 20% of the household population was
199 divided into five equal categories from poorest to richest. (19).

200 The score for the level of belief in the effectiveness of IPTp-SP and malaria morbidity was
201 generated using a three-point Likert scale (22). The level of belief score about the effectiveness of
202 IPTp-SP from two survey questions (19): “*does malaria preventive medicine keep the mother*
203 *healthy?*” “*Does malaria preventive medicine keep the baby healthy?*” Also, the level of belief
204 score about malaria morbidity was derived from the following four survey questions (19): “*can*
205 *malaria lead to death?*” “*can malaria make people dangerously sick?*” “*only weak children die*
206 *of malaria?*” “*Do not worry about malaria can be cured?*” The women’s responses to the
207 abovementioned questions asked in the Nigeria DHS were scored using a three-point Likert scale
208 such that 1 = Disagree, 2 = Do not know, and 3 = Agree (22). After that, row mean scores were
209 calculated for the women’s array of responses to these questions using the “egen” command on
210 STATA. A score of one was the least possible score, and three was the highest possible score.
211 Finally, the terciles of the composite scores were used as a cut-off to categorise the level of belief
212 scores into low (1.0 – 1.9), average (2.0) and high scores (2.1 – 3.0).

213 **Data management and analysis**

214 Data extraction, cleaning, re-coding and analysis were done using Stata version 16 (23). The
215 extracted data were restricted to only women with live births during or two years before the 2018
216 NDHS. However, in creating the outcome variable, women who did not know if they took
217 SP/Fansidar and the number of doses of SP/Fansidar taken was dropped, that is, 171 and 127
218 women, respectively. All selected exposure variables were categorical, and the missing
219 observations across the exposure variables were reported as missing responses. Finally, the cleaned
220 dataset was saved independently and converted into a survey dataset by applying the weighting,

221 stratification and clustering. Proportions and frequencies were used to summarise all categorical
222 variables for the descriptive analysis. At the same time, bivariate and multivariable logistic
223 regression were used in the analytical analysis. The bivariate and multivariable logistic regression
224 models were fitted using a four-step approach for modelling survey data as Heeringa et al., 2017
225 (59) and Hosmer and Lemeshow 2000 (60) recommended. The four-step approach is detailed
226 below:

227 First, we fitted a bivariate logistic regression model to estimate the association of the outcome
228 variables (at least one dose and optimal uptake) to each exposure variable. Second, all exposure
229 variables with a p-value of <0.10 from the bivariate models were selected as candidates for main
230 effects in the multivariable logistic regression model. Building the final multivariable logistic
231 regression model involved an iterative process—the exposure variables of importance identified
232 by previous studies were arranged from highest to the least importance. Third, fitted different
233 model specifications by manually adding or dropping each exposure variable by performing the
234 adjusted Wald test to assess each exposure variable's contribution to the model. Lastly,
235 scientifically plausible interactions among the exposure variables were checked. The interaction
236 term was assessed by specifying factorial interaction using binary operators ($\#\#$). The selection of
237 the variables to interact was based on epidemiological notions or from previous literature.
238 However, the selected multivariable logistic regression model accounted for only interaction terms
239 with a p-value $< 5\%$. Then, the fit of the final model was assessed using the Hosmer-Lemeshow
240 goodness-of-fit test. The final models estimated the adjusted odds ratios (aORs). The significance
241 level used was less than 5% (<0.05), two-tailed at 95% confidence intervals.

242 **Ethical consideration**

243 The Nigeria DHS 2018 was conducted by the Nigerian Population Commission in collaboration
244 with the National Malaria Elimination Programme (NMEP) of the Federal Ministry of Health,
245 Nigeria. Before each interview during the 2018 NDHS survey, all respondents above 18 years
246 provided written informed consent, and for those under 18 years of age written informed consent
247 was obtained from the parent/guardian. The fieldworker ensured confidentiality throughout the
248 survey process. The respondents' records were coded and de-identified (19). For this study,
249 permission for NDHS 2018 dataset for secondary data analysis has been obtained from ICF
250 International – Measure DHS website. Ethics approval was obtained from the University of the
251 Witwatersrand Human Research Ethics Committee (Medical) – **M2011103**.

252

253

254

255

256

257

258

259

260 **Results**

261 **General characteristics of study participants**

262 The study included 12,742 pregnant women between 15 and 49 years with live births from the
263 2018 NDHS. The mean age was 28.3 ± 6.7 years old. The study participants were selected from
264 all the six regions (geo-political zones) in varying proportions. Of which majority of them were
265 lived in Northwest Nigeria. 12,180 (95.6%) were married or living with a man, while 561 (4.4%)
266 were single, divorced or widows. Of these women, 6692 (52.7%) had less than four children,
267 whereas 6049 (47.5%) had four or more children. Also, more than half of the women, 7888
268 (61.9%), resided in rural Nigeria. In addition, the distribution of study participants varied
269 depending on maternal characteristics, 5,766 (45.3%) of study participants had no formal
270 education, and 4568 (35.9%) of them had husbands/spouses with no formal education. Although
271 8827 (69.3%) of the study participants were gainfully employed, only 2.0% subscribed to health
272 insurance coverage. Additionally, 75.8% of them attended ANC services during pregnancy, of
273 which 56.1% visited the ANC clinic more than four times in 2018. In the same year, almost half
274 (47.1%) of the study participants initiated ANC services in their second trimester. Details of the
275 characteristics of the study participants are presented in [Table 2](#).

276

277

278

279

280

281

282

283

284 **Table 2: Study characteristics of pregnant women aged 15 to 49 years old**

Characteristics	Categories	Frequency N(%)
Total		12,742 (100%)
Sociodemographic characteristics		
Age in years Mean age: 28.3 years old Standard deviation: 6.7 years	15-24	3842 (30.2)
	25-34	6242 (49.0)
	35+	2657 (20.9)
Marital status	Unmarried	561 (4.4)
	Married	12,180 (95.6)
Household wealth Index	Poorest	2,763 (21.7)
	Poorer	2,933 (23.0)
	Middle	2,636 (20.7)
	Richer	2,358 (18.5)
	Richest	2052 (16.1)
Region	North Central	1,770 (13.9)
	North East	2,339 (18.4)
	North West	4,638 (36.4)
	South East	1,263 (9.9)
	South-South	1,126 (8.8)
	South West	1,606 (12.6)
Residential areas	urban	4,854 (38.1)
	rural	7,888 (61.9)
Highest Educational Levels	No Education	5,766 (45.3)
	Primary	1,856 (14.6)
	Secondary	4,050 (31.8)
	Higher	1,070 (8.4)
Employment status	Not Employed	3,915 (30.7)
	Employed	8,827 (69.3)
Spouse's Education Level	No Education	4,568 (35.9)
	Primary	1,624 (12.7)
	Secondary	4,116 (32.7)
	Higher	1,873 (14.7)
	Missing	561 (4.4)
Pregnancy-related characteristics		
Frequency of ANC Visits	No ANC Visit	3,081 (24.2)
	< 4 ANC Visits	2,350 (18.4)
	≥4 ANC Visits	7,151 (56.1)
	Missing Response	160 (1.3)
ANC Initiation	1st Trimester	2,273 (17.8)
	2nd Trimester	6,003 (47.1)
	3rd Trimester	1,366 (10.7)
	Missing	3,100 (24.3)
Number of children born	Less than four children	6692 (52.7)
	Four or more children	6049 (47.5)

Knowledge of malaria-related characteristics		
Belief in Effectiveness of IPTp-SP	Low	200 (1.6)
	Average	504 (4.0)
	High	12,038 (94.5)
Belief about Malaria morbidity	Low	1,614 (12.7)
	Average	3,869 (30.4)
	High	7,259 (57.0)
Health Insurance Coverage	No	12,484 (98.0)
	Yes	258 (2.0)
Exposed to media messages	No	11,823 (92.8)
	Yes	919 (7.2)

285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304

305 **Prevalence of IPTp-SP uptake among pregnant women in 2018**

306 The estimated prevalence of at least one IPTp-SP dose was 63.6% (95% CI: 62.0–65.1), and three
307 or more IPTp-SP doses were 16.8% (95% CI: 15.9–17.8) among pregnant women in Nigeria ([Table](#)
308 [3](#)). Yet, the prevalence varied significantly depending on the maternal characteristics except for
309 marital status. For instance, the prevalence of at least one SP was highest among women aged 25
310 to 34 years at 64.9% (95% CI: 63.0 – 66.7). Similarly, women aged 25 to 34 also reported the
311 highest uptake of three or more SP doses at 17.7% (95% CI: 16.5 –19.0). The result indicated that
312 the higher the educational attainment among women, the higher the number of IPTp-SP doses
313 received during pregnancy. Also, among pregnant women, the number of IPTp-SP doses received
314 during pregnancy increased depending on their spouse’s educational level. Likewise, there was an
315 increasing prevalence of SP doses among pregnant women from the poorest to the wealthiest
316 household wealth index ($p < 0.001$). The result also established that the frequency of ANC visits
317 was directly related to the number of SP doses they take during pregnancy ($p < 0.001$). The
318 prevalence of at least one IPTp-SP dose at 80.3% (95% CI: 78.8 – 81.7) as well as the prevalence
319 of optimal SP doses at 23.3% (95% CI: 22.0 – 24.6) was the highest uptake was highest for those
320 who attended more than four ANC visits during pregnancy. Also, early initiation of antenatal care
321 was related to a higher prevalence of at least one dose and optimal doses of SP ($p < 0.001$). The
322 prevalence of taking at least one dose and optimal SP doses was significantly related to the belief
323 in the effectiveness of IPTp-SP for protection against malaria in pregnancy ($p < 0.001$). In addition,
324 the prevalence of at least one IPTp-SP dose differed based on the level of belief about morbidities
325 caused by malaria ($p < 0.001$) but not the prevalence of taking optimal SP doses ($p = 0.242$).

326 Table 3: Prevalence of IPTp-SP dose received by pregnant women aged 15 to 49 years in 2018

Factors	Total N (%)	% Women who received ≥ 1 dose		p-value	% Women who received ≥ 3 Doses		p-value
		n ^a (%)	95% CI		n ^b (%)	95% CI	
Uptake of SP dose	12742 (100%)	8098 (63.6)	62.0 – 65.1		2143 (16.8)	15.9 – 17.8	
Age in years				0.015*			0.010*
15-24	3842 (30.2)	2352 (61.2)	58.8 – 63.6		578 (15.0)	13.6 – 16.6	
25-34	6242 (49.0)	4049 (64.9)	63.0 – 66.7		1103 (17.7)	16.5 – 19.0	
35+	2657 (20.9)	1697 (63.9)	61.3 – 66.7		462 (17.4)	15.7 – 19.3	
Region				<0.001*			<0.001*
North Central	1770 (13.9)	1003 (56.7)	53.2 – 60.1		264 (14.9)	13.1 – 17.0	
North East	2339 (18.4)	1520 (65.0)	61.8 – 68.0		329 (14.1)	12.1 – 16.3	
North West	4939 (36.4)	2712 (58.5)	55.1 – 61.7		503 (10.8)	9.4 – 12.4	
South East	1263 (9.9)	1003 (79.5)	76.4 – 82.2		493 (39.1)	35.9 – 42.3	
South South	1129 (8.8)	837 (74.3)	71.6 – 76.9		275 (24.4)	21.6 – 27.6	
South West	1606 (12.6)	1023 (62.7)	59.9 – 67.3		279 (17.4)	14.6 – 20.5	
Residential areas				<0.001*			<0.001*
Urban	4853 (38.1)	3524 (72.6)	70.4 – 74.7		1032 (21.3)	19.6 – 23.0	
Rural	7888 (61.9)	4574 (58.0)	55.9 – 60.1		1112 (14.1)	13.0 – 15.3	
Marital status				0.980			0.753
Unmarried	561 (4.4)	357 (63.6)	59.0 – 68.0		98 (17.4)	14.1 – 21.3	
Married	12,180 (95.6)	7741 (63.6)	61.9 – 65.2		2046 (16.8)	15.8 – 17.9	
Highest Educational level				<0.001*			<0.001*
No Education	5766 (45.3)	2953 (51.2)	48.7 – 53.7		597 (10.4)	9.3 – 11.6	
Primary	1856 (14.6)	1259 (67.8)	65.2 – 70.4		340 (18.3)	16.4 – 20.4	
Secondary	4050 (31.8)	3008 (74.3)	72.5 – 75.9		938 (23.2)	21.6 – 24.9	
Higher	1070 (8.4)	878 (82.1)	79.2 – 84.7		268 (25.0)	21.7 – 28.8	
Household Wealth Index				<0.001*			<0.001*
Poorest	2763 (21.7)	1325 (47.9)	44.8 – 51.1		335 (12.1)	10.5 – 14.0	
Poorer	2933 (23.0)	1593 (54.3)	51.2 – 57.4		323 (11.0)	9.6 – 12.6	

Middle	2636 (20.7)	1793 (68.0)	65.7 – 70.3		423 (16.1)	14.3 – 18.0	
Richer	2358 (18.5)	1728 (73.3)	70.7 – 75.7		550 (23.3)	21.0 – 25.9	
Richest	2052 (16.1)	1659 (80.8)	78.3 – 83.2		512 (24.9)	22.3 – 27.8	
Employment Status				<0.001*			<0.001*
Not Employed	3915 (30.7)	2247 (57.4)	54.8 – 60.0		539 (13.8)	12.3 – 15.4	
Employed	8827 (69.3)	5851 (66.3)	64.7 – 67.9		1604 (18.2)	17.1 – 19.3	
Spouse's Educational Level				<0.001*			<0.001*
No Education	4568 (35.9)	2160 (47.3)	44.6 – 47.0		392 (8.6)	7.4 – 9.9	
Primary	1624 (12.7)	1058 (65.2)	62.1 – 68.2		248 (15.3)	13.3 – 17.5	
Secondary	4116 (32.7)	3020 (73.4)	71.6 – 75.1		974 (23.7)	22.0 – 25.4	
Higher	1872 (14.7)	1502 (80.3)	77.9 – 82.5		431 (23.0)	20.5 – 25.8	
Missing Response	561 (4.4)						
Frequency of ANC Visits				<0.001*			<0.001*
No ANC Visit	3081 (24.1)	508 (16.5)	14.7 – 18.5		134 (4.4)	3.4 – 5.5	
<4 ANC Visits	2350 (18.4)	1717 (73.1)	70.7 – 75.3		297 (12.6)	11.0 – 14.4	
≥ 4 ANC Visits	7151 (56.1)	5739 (80.3)	78.8 – 81.7		1667 (23.3)	22.0 – 24.6	
Missing Response	160 (1.3)						
Timing of ANC initiation				<0.001*			<0.001*
1st Trimester	2273 (17.8)	1813 (79.8)	77.5 – 81.9		640 (28.2)	25.8 – 30.6	
2nd Trimester	6003 (47.1)	4752 (79.2)	77.6 – 80.7		1177 (19.6)	18.3 – 21.0	
3rd Trimester	1365 (10.7)	1007 (73.8)	70.9 – 76.5		186 (13.6)	11.5 – 16.1	
Missing Response	3100 (24.3)						
Number of children born				<0.001*			<0.001*
Less than 4 children	6692 (52.7)	4438 (66.3)	64.6 – 68.0		1226 (18.3)	17.1 – 19.6	
Four or more children	6049 (47.5)	3660 (60.5)	58.4 – 62.5		917 (15.2)	14.0 – 16.4	
Media Exposure				<0.001*			<0.001*
No	11822 (92.8)	7349 (62.2)	60.5 – 63.8		1855 (15.7)	14.8 – 16.7	
Yes	919 (7.2)	749 (81.5)	78.1 – 84.6		288 (31.3)	26.9 – 36.2	
Health Insurance coverage				0.001*			<0.001*
No	12484 (98.0)	7889 (63.2)	61.6 – 64.8		2072 (16.6)	15.6 – 17.6	
Yes	257 (2.0)	209 (81.2)	71.6 – 88.0		72 (27.8)	21.9 – 34.6	

Belief in Effectiveness of SP				<0.001*			<0.001*
Low level of belief	200 (1.6)	86 (43.0)	35.7 – 50.7		14 (7.2)	4.5 – 11.4	
Average level of belief	504 (4.0)	174 (34.4)	28.6 – 40.7		52 (10.4)	7.3 – 14.6	
High level of belief	12038 (94.5)	7838 (65.1)	63.5 – 66.7		2077 (17.3)	16.3 – 18.3	
Belief about Malaria morbidity				<0.001*			0.242
Low level of belief	1614 (12.7)	912 (56.5)	52.4 – 59.2		240 (14.9)	12.7 – 16.7	
Average level of belief	3869 (30.4)	5400 (62.8)	61.2 – 65.9		648 (16.8)	15.6 – 19.7	
High level of belief	7258 (57.0)	134 (65.5)	63.4 – 67.2		1255 (17.3)	15.8 – 18.2	
ANC: Antenatal Care, *potential candidate for the multivariable logistic regression							

328 **Factors associated with uptake of at least one IPTp-SP dose**

329 The results indicated that all selected maternal characteristics were independently associated with
330 receiving at least one IPTp-SP dose during pregnancy ([Table 4](#)). Yet, after adjusting for other
331 factors in the multivariable model, uptake of at least one IPTp-SP dose was significantly associated
332 with pregnant women's age group, the region where they live, and the frequency of ANC visits.
333 Also, women's belief in the effectiveness of SP for malaria treatment and about morbidities caused
334 by malaria influenced their decision to initiate antimalaria treatment during pregnancy. For
335 instance, pregnant women aged 35 and above had a 42% higher likelihood of receiving at least the
336 first dose than those aged 15 to 24 (aOR:1.42; 95% CI: 1.12–1.81). Also, women living in the
337 south-west were 50% less likely to receive at least one dose than North-Central (aOR: 0.50; 95%
338 CI: 0.38 – 0.64). The results also indicated that those with four or more ANC visits had 61% greater
339 odds of taking at least one SP dose than those with fewer ANC attendance (aOR: 1.61; 95% CI:
340 1.36–1.91). The timing of ANC initiation showed no significant association with using at least one
341 IPTp-SP dose ($p = 0.138$). Those who somewhat believed in the drug's effectiveness were 50%
342 less likely to receive at least a single SP dose than those with a minimal belief (aOR:0.50; 95% CI:
343 0.26–1.00). Conversely, the awareness of morbidities caused by malaria during pregnancy
344 predicted a higher uptake of at least one SP dose ($p = 0.013$). Those with firm beliefs were 33%
345 more likely to receive at least a single IPTp-SP dose than those unaware of malaria-associated
346 morbidities (aOR: 1.33; 95% CI: 1.10–1.62). The household wealth index and spouse's
347 educational level interacted significantly with the uptake of at least one SP dose ($p = 0.048$). As a
348 result, women in the wealthiest household whose husbands had secondary education had a four-
349 fold higher odds of receiving at least one dose of IPTp-SP than those impoverished with no formal
350 education (aOR:4.17; 95% CI:1.11–8.85).

351 **Table 4: Factors associated with uptake of at least one SP dose among pregnant women**

Factors	Total N (%)	Crude OR (95% CI) Uptake of at least one dose	P-value	Adjusted OR (95%CI) Uptake of at least one dose	P-value
Socio-demographic Factors					
Age in years			0.011^a		0.008^a
15-24	3,842 (30.2)	1.00		1.00	
25-34	6,242 (49.0)	1.17 (1.06 - 1.29)	0.003	1.10 (0.92 - 1.31)	0.287
35+	2,657 (19.3)	1.12 (0.98 - 1.28)	0.100	1.42 (1.12 - 1.81)	0.004
Region			<0.001^a		<0.001^a
North Central	1,770 (13.9)	1.00		1.00	
North East	2,339 (18.4)	1.42 (1.17 - 1.73)	<0.001	2.05 (1.63 - 2.59)	<0.001
North West	4,639 (36.4)	1.08 (0.88 - 1.31)	0.465	2.53 (1.98 - 3.23)	<0.001
South East	1,263 (9.9)	2.96 (2.36 - 3.71)	<0.001	1.33 (1.01 - 1.74)	0.039
South South	1,126 (8.8)	2.22 (1.817 - 2.700)	<0.001	1.61 (1.23 - 2.11)	0.001
South West	1,606 (12.6)	1.34 (1.08 - 1.66)	0.007	0.50 (0.38 - 0.64)	<0.001
Residential areas			<0.001^a		0.087^a
Urban	4,854 (38.1)	1.00		1.00	
Rural	7,888 (61.9)	0.52 (0.45 - 0.60)	<0.001	1.15 (0.98 - 1.36)	0.087
Highest Educational Level			<0.001^a		0.854^a
No Education	5,766 (45.3)	1.00		1.00	
Primary	1,856 (14.6)	2.01 (1.74 - 2.33)	<0.001	1.01 (0.84 - 1.22)	0.902
Secondary	4,050 (31.8)	2.75 (2.41 - 3.14)	<0.001	0.94 (0.77 - 1.15)	0.530
Higher	1,070 (8.4)	4.371 (3.53 - 5.42)	<0.001	0.92 (0.67 - 1.25)	0.585
Household wealth Index			<0.001^a		0.846^a
Poorest	2,763 (21.7)	1.00		1.00	
Poorer	2,933 (23.0)	1.29 (1.10 - 1.51)	0.001	0.93 (0.71 - 1.21)	0.583
Middle	2,636 (20.7)	2.31 (1.97 - 2.72)	<0.001	1.07 (0.77 - 1.48)	0.698
Richer	2,358 (18.5)	2.98 (2.49 - 3.57)	<0.001	1.20 (0.69 - 2.08)	0.515
Richest	2,052 (16.1)	4.58 (3.75 - 5.61)	<0.001	0.94 (0.38 - 2.37)	0.902
Employment Status			<0.001^a		0.693^a
Not Employed	3,915 (30.7)	1.00		1	
Employed	8,827 (69.3)	1.46 (1.31 - 1.62)	<0.001	1.03 (0.89 - 1.19)	0.693
Spouse's Education Level			<0.001^a		0.695^a
No Education	4,568 (35.6)	1.00		1.00	
Primary	1,624 (12.7)	2.09 (1.77 - 2.46)	<0.001	1.10 (0.66 - 1.82)	0.721
Secondary	4,116 (32.7)	3.07 (2.69 - 3.51)	<0.001	1.04 (0.70 - 1.51)	0.882
Higher	1,872 (14.7)	4.54 (3.80 - 5.42)	<0.001	1.95 (0.61 - 6.36)	0.261
Pregnancy-related factors					
Frequency of ANC visits			<0.001^a		<0.001^a
<4 ANC Visits	2,351 (24.7)	1.00		1.00	
≥ 4 ANC Visits	7,151 (75.3)	1.50 (1.31 - 1.72)	<0.001	1.61 (1.36 - 1.91)	<0.001
Timing of ANC Initiation			0.001^a		0.138^a

1st Trimester	2,273 (23.6)	1.00		1.00	
2nd Trimester	6,003 (62.3)	0.96 (0.83 - 1.12)	0.631	0.98 (0.83 - 1.15)	0.780
3rd Trimester	1,365 (14.2)	0.71 (0.59 - 0.86)	<0.001	0.81 (0.65 - 1.02)	0.080
Number of children born			<0.001^a		0.328^a
<4 children	6692 (52.7)	1.00		1.00	
4+ children	6049 (47.5)	0.78 (0.71 - 0.85)	<0.001	0.92 (0.77 - 1.09)	0.328
Knowledge of malaria-related factors					
Media Exposure			<0.001^a		0.175^a
No	11,823 (92.8)	1.00		1.00	
Yes	919 (7.2)	2.69 (2.14 - 3.37)	<0.001	1.20 (0.92 - 1.56)	0.175
Health Insurance coverage			0.001^a		0.082^a
No	12,484 (98.0)	1.00		1.00	
Yes	258 (2.0)	2.51 (1.47 - 4.28)	0.001	1.51 (0.26 - 1.00)	0.053
Belief in Effectiveness of SP			<0.001^a		<0.001^a
Low belief	200 (1.6)	1.00		1.00	
Average belief	504 (4.0)	0.69 (0.47 - 1.03)	0.072	0.50 (0.26 - 1.00)	0.053
High belief	12,038 (94.5)	2.47 (1.81 - 3.38)	<0.001	1.51 (0.90 - 2.51)	0.116
Belief about Malaria morbidity			<0.001^a		0.013^a
Low belief	1,615 (12.7)	1.00		1.00	
Average belief	3,869 (30.4)	1.38 (1.17 - 1.62)	<0.001	1.32 (1.05 - 1.67)	0.017
High belief	7,258 (57.0)	1.49 (1.29 - 1.72)	<0.001	1.33 (1.10 - 1.62)	0.003
<p><i>ANC – Antenatal care</i> ^a<i>p-values – overall p-values for each exposure variable in the model, CI – Confidence Intervals</i> <i>OR – Odds ratios, crude OR (from Bivariate analysis) Adjusted OR (from Multivariable analysis)</i> Goodness-of-fit of the model = F(9, 1262) = 0.651; p = 0.754 1 => Reference category</p>					

352

353

354

355

356

357

358

359

360

361 **Factors associated with the uptake of optimal doses of IPTp-SP**

362 All included maternal characteristics in the study were independently associated with the uptake
363 of at least three IPTp-SP doses ([Table 5](#)). However, after adjusting for all factors in the model,
364 household wealth index, frequency of ANC visits, and ANC initiation were significantly related
365 to taking at least three IPTp-SP doses. The result established that compared to women with no
366 formal education, those with higher education were 30% less likely to take at least three SP doses
367 (aOR: 0.70 95% CI:0.51–0.98). In contrast, women whose spouses attained higher education had
368 an 85% probability of completing optimal doses than those whose spouses had no formal education
369 (aOR: 1.85; 95% CI: 1.39–2.46). Unexpectedly, the uptake of optimal IPTp-SP doses was
370 inversely associated with the household wealth index. Compared to women in most impoverished
371 households, the probability of taking at least three SP doses was reduced by 35% among women
372 in poorer households and middle class (aOR: 0.65; 95% CI:0.52–0.82) and decreased by 29%
373 among wealthiest households (aOR: 0.71; 95% CI: 0.52 – 0.97). Furthermore, the probability of
374 completing at least three doses among pregnant women who attended four or more ANC visits was
375 57% higher than those with fewer ANC visits (aOR: 1.57; 95% CI:1.31 – 1.88). Conversely, the
376 timing of initiating ANC services predicted a negative association with taking optimal SP doses
377 during pregnancy ($p < 0.001$). Those who initiated ANC in their third trimester were 39% less
378 likely to complete optimal IPTp-SP doses during pregnancy (aOR:0.61; 95% CI: 0.47-0.79). Also,
379 pregnant women exposed to media messages were 1.39 times as likely to complete optimal doses
380 of IPTp-SP than those not exposed to media messages (aOR: 1.39; 95% CI: 1.10 – 1.75). Also, the
381 receipt of optimal doses was associated with the level of belief about morbidity caused by malaria
382 ($p = 0.021$). In contrast, the belief level in the effectiveness of SP against malaria in pregnancy did
383 not play a role in taking IPTp-SP ($p=0.102$)

384 **Table 5: Factors associated with uptake of optimal doses of IPTp-SP among pregnant**
 385 **women**

Factors	Total N (%)	Crude OR (95% CI) Uptake of optimal doses	p-value	Adjusted OR (95% CI) Uptake of optimal doses	p-value
Sociodemographic factors					
Age in years			0.015^a		0.583^a
15-24	3,842 (30.2)	1.00		1.00	
25-34	6,242 (49.0)	1.21 (1.06 - 1.38)	0.004	1.07 (0.90 - 1.27)	0.420
35+	2,462 (19.3)	1.19 (1.01 - 1.40)	0.036	1.14 (0.89 - 1.46)	0.300
Region			<0.001^a		<0.001^a
North Central	1,770 (13.9)	1.00		1.00	
North East	2,339 (18.4)	0.93 (0.74 - 1.18)	0.558	0.90 (0.70 - 1.15)	0.116
North West	4,639 (36.4)	0.69 (0.56 - 0.86)	0.001	0.97 (0.76 - 1.24)	0.475
South East	1,263 (9.9)	3.65 (2.98 - 4.48)	<0.001	2.96 (2.31 - 3.80)	0.187
South South	1,126 (8.8)	1.84 (1.48 - 2.30)	<0.001	1.58 (1.20 - 2.06)	<0.001
South West	1,606 (12.6)	1.20 (0.28 - 1.55)	0.166	0.82 (0.63 - 1.06)	<0.001
Residential areas			<0.001^a		0.240^a
Urban	4,854 (38.1)	1.00		1.00	
Rural	7,888 (61.9)	0.61 (0.53 - 0.70)	<0.001	1.11 (0.93 - 1.31)	0.240
Highest Educational Level			<0.001^a		0.168^a
No Education	5,766 (45.3)	1.00		1.00	
Primary	1,856 (14.6)	1.94 (1.63 - 2.31)	<0.001	0.97 (0.80 - 1.17)	0.749
Secondary	4,050 (31.8)	2.61 (2.25 - 3.04)	<0.001	0.85 (0.68 - 1.03)	0.115
Higher	1,070 (8.4)	2.89 (2.31 - 3.62)	<0.001	0.70 (0.51 - 0.98)	0.035
Household Wealth Index			<0.001^a		0.003^a
Poorest	2,763 (21.7)	1.00		1.00	
Poorer	2,933 (23.0)	0.90 (0.72 - 1.11)	0.326	0.65 (0.52 - 0.82)	<0.001
Middle	2,636 (20.7)	1.38 (1.12 - 1.71)	0.003	0.65 (0.51 - 0.82)	<0.001
Richer	2,358 (18.5)	2.20 (1.78 - 2.73)	<0.001	0.82 (0.65 - 1.04)	0.088
Richest	2,052 (16.1)	2.41 (1.93 - 2.30)	<0.001	0.71 (0.52 - 0.97)	0.027
Employment Status			<0.001^a		0.668^a
Not Employed	3,915 (30.7)	1.00		1.00	
Employed	8,827 (69.3)	1.39 (1.21 - 1.60)	<0.001	0.97 (0.82 - 1.13)	0.668
Spouse's Educational Level			<0.001^a		<0.001^a
No Education	4,568 (35.6)	1.00		1.00	
Primary	1,624 (12.7)	1.92 (1.55 - 2.39)	<0.001	1.06 (0.84 - 1.34)	0.611
Secondary	4,116 (32.7)	3.30 (2.76 - 3.93)	<0.001	1.70 (1.39 - 2.08)	<0.001
Higher	1,872 (14.7)	3.19 (2.568 - 3.961)	<0.001	1.85 (1.39 - 2.46)	<0.001
Pregnancy-related factors					
Frequency of ANC Visits			<0.001^a		<0.001^a
<4 ANC Visits	2,351 (24.7)	1.00		1.00	

≥4 ANC Visits	7,151 (75.3)	2.10 (1.79 - 2.47)	<0.001	1.57 (1.31 - 1.88)	<0.001
Timing of ANC Initiation			<0.001^a		<0.001^a
1st Trimester	2,273 (23.6)	1.00		1.00	
2nd Trimester	6,003 (62.3)	0.62 (0.54 - 0.71)	<0.001	0.71 (0.61 - 0.82)	<0.001
3rd Trimester	1,365 (14.2)	0.40 (0.32 - 0.50)	<0.001	0.61 (0.47 - 0.79)	<0.001
Number of children born			<0.001^a		0.681^a
<4 children	6692 (52.7)	1.00		1.00	
4+ children	6049 (47.5)	0.80 (0.72 - 0.89)	<0.001	0.96 (0.81 - 1.14)	0.681
Knowledge of malaria-related factors					
Media Exposure			<0.001^a		0.007^a
No	11,823 (92.8)	1.00		1.00	
Yes	919 (7.2)	2.45 (1.96 - 3.07)	<0.001	1.38 (1.10 - 1.75)	0.007
Health Insurance coverage			<0.001^a		0.076^a
No	12,484 (98.0)	1.00		1.00	
Yes	258 (2.0)	1.94 (1.41 - 2.66)	<0.001	1.37 (0.97 - 1.94)	0.076
Belief in Effectiveness of SP			<0.001^a		0.102^a
Low	200 (1.6)	1.00		1.00	
Average	504 (4.0)	1.49 (0.78 - 2.85)	0.223	1.17 (0.54 - 2.55)	0.694
High	12,038 (94.5)	2.68 (1.62 - 4.44)	<0.001	1.63 (0.92 - 2.88)	0.093
Belief about Malaria morbidity			0.074^a		0.021^a
Low	1,615 (12.7)	1.00		1.00	
Average	3,869 (30.4)	1.25 (1.01 - 1.54)	0.037	1.14 (0.91 - 1.42)	0.250
High	7,258 (57.0)	1.20 (1.01 - 1.43)	0.041	0.90 (0.73 - 1.10)	0.305
<p><i>uptake of optimal doses of IPTp-SP implies uptake of at least three doses of IPTp-SP;</i> <i>ANC – Antenatal care</i> ^a<i>p-values – overall p-values for each exposure variable in the model, CI – Confidence Intervals</i> <i>OR – Odds ratios, crude OR (from Bivariate analysis), Adjusted OR (from Multivariable analysis)</i> Goodness-of-fit of the model = F(9, 1262) = 0.222; p = 0.991 1 => Reference category</p>					

386

387

388 **Discussion**

389 This study established the prevalence of IPTp-SP and the factors associated with the uptake of at
390 least one dose and at least three doses of IPTp-SP among pregnant women in Nigeria. The study
391 found a low and regional disparities in prevalence of IPTp-SP uptake during pregnancy. Several
392 maternal characteristics such as, age group, education, antenatal care attendance, household wealth
393 index and spouse's educational attainment were found to contribute to the low IPTp-SP uptake
394 during pregnancy in Nigeria.

395 In this study, compared with at least one SP dose at 63.6%, the prevalence of three or more SP
396 doses was much lower at 16.8% among pregnant women in Nigeria. These findings fall
397 significantly below the National Malaria Elimination Programme's stipulated target for 100% of
398 pregnant women attending ANC in Nigeria to receive at least three IPTp-SP doses by 2020 (24).

399 A similar low prevalence of at least one dose at 62% and three or more IPTp-SP doses at 32%
400 across sub-Saharan African countries were reported in the WHO malaria report in 2019 (1).
401 According Hill *et al.*, 2013, differences in maternal characteristics across and within countries in
402 sub-Saharan Africa contributed to low IPTp-SP prevalence of IPTp-SP (8). Also, Pons-Duran *et*
403 *al.*, 2020 reported that the prevalence of taking optimal IPTp-SP doses was significantly below
404 25% in DR Congo, Madagascar and Nigeria (10). Conversely, the literature revealed the
405 prevalence of IPTp-SP uptake is somewhat higher at 46%, 63% and 42% in Uganda (25), Ghana
406 (13), and Malawi (26), respectively.

407 Several sociodemographic characteristics were established as factors associated with the uptake
408 of at least one IPTp-SP dose. In terms of age group, women aged 35 years and above had higher
409 odds of receiving at least one IPTp-SP dose during pregnancy. This finding was consistent with

410 Olugbade *et al.*, 2019 in Nigeria (27) and Kibusi *et al.*, 2015 in Tanzania (28). The higher uptake
411 of at least one dose among older women may be attributed to earlier exposure to the benefit of
412 IPTp-SP during prior pregnancies (29). In contrast, pregnant women's age group did not play a
413 significant role in taking optimal antimalarial regimens, as supported by Hill *et al.*, 2013 (8).
414 Women residing in Northern Nigeria had the highest likelihood of taking at least one IPTp-SP
415 dose due to a noticeable influence of Non-governmental Organisations in supporting increase
416 access to healthcare interventions in the region (30). This regional variation in the level of IPTp-
417 SP is consistent in other sub-Saharan African countries (8). This evidence may be due to inequality
418 in accessing care in Nigeria, as Olukoya and Adebisi reported in 2017 (23).

419 The finding agrees with Yaya *et al.*, 2018, who found that pregnant women's educational status in
420 malaria-endemic countries negatively predicted optimal IPTp-SP doses (12). The result suggests
421 that level of education can contribute to poor adherence to receiving optimal antimalarial regimens
422 during pregnancy. The opposite is accurate regarding the association between uptake of IPTp-SP
423 and the spouse's educational level. The current findings agree with studies conducted in Eastern
424 Nigeria (31). The findings infer that male involvement in ANC services during pregnancy might
425 predict a higher IPTp-SP uptake (32). Utilising at least one dose and optimal IPTp-SP doses are
426 associated with the household wealth index in different directions. Previous studies established a
427 positive association between receiving optimal IPTp-SP doses and the household's wealth index
428 (10,11). However, this current study found that pregnant women have reduced odds of receiving
429 the optimal doses of IPTp-SP regardless of their wealth index. Conversely, Muhammed *et al.*, 2020
430 found that pregnant women from the wealthiest households have increased IPTp-SP uptake than
431 those from the poorest households in Nigeria (11). The disparity in the results may be attributed to
432 the different methodologies adopted in assessing the association between wealth index and uptake

433 of IPTp-SP. The current study reported that 84.3% of pregnant women who did not receive the
434 optimal doses of IPTp-SP were also not exposed to media messages. The results may be a plausible
435 reason for the wealth index indirectly influencing the uptake of optimal doses of IPTp-SP in this
436 study. Regardless of the wealth index, studies support the evidence that knowledge of malaria-
437 related interventions may affect adherence to completing three or more IPTp-SP doses during
438 pregnancy (8,15)

439 Early commencement of ANC services (timing of ANC initiation) implied an increased likelihood
440 of initiating the first dose and completing at least three IPTp-SP doses during pregnancy. This
441 finding aligns with the new IPTp-SP policy, which recommends the uptake of the first IPTp-SP
442 dose after the first trimester during pregnancy and then successive IPTp-SP doses received in each
443 scheduled ANC visit at a one-month interval (5). Studies conducted in Tanzania (16), Uganda (25),
444 Malawi (33), and Nigeria (11) established similar findings. Also, ANC attendance was
445 significantly associated with IPTp-SP uptake, as supported by Hill et al., 2013, a study conducted
446 in SSA countries, including Nigeria (8). Among the study participants who visited the ANC clinic
447 at least four times during pregnancy in 2018, approximately 84% of them initiated ANC services
448 in their second trimester. Yet, only 23.3% received three or more IPTp-SP doses, though 80.3%
449 received at least the first SP dose during pregnancy. This evidence implies lost opportunities to
450 deliver the optimal IPTp-SP doses to pregnant women who visited ANC clinics at least four times.
451 Even though the WHO recommends delivering IPTp-SP via scheduled ANC services to pregnant
452 women living in malaria-endemic countries, the findings in Nigeria suggest otherwise. As evident
453 in previous studies, the low IPTp-SP uptake via the ANC platform may be attributed to identified
454 healthcare system constraints such as non-compliance to IPTp-SP guidelines (34), a shortage of

455 trained healthcare workers (35), occasional SP stock-out (34,35) and inadequate knowledge or
456 awareness about IPTp-SP guidelines (36).

457 The finding suggests that exposure to malaria-related messages at least once a week may increase
458 the odds of being aware of the benefits of IPTp-SP during pregnancy. This increased awareness
459 may translate to higher chances of taking three or more IPTp-SP doses by pregnant women. Similar
460 results have been found in Ghana (13), Uganda (25) and Tanzania (16). Furthermore, among
461 pregnant, there was a direct association between taking IPTp-SP and their belief in its effectiveness
462 against malaria infection. Such that their level of belief may explain their level of trust in the
463 efficacy and safety of IPTp-SP. In this study, the findings suggest that women with less belief in
464 the effectiveness of IPTp-SP were less likely to initiate IPTp-SP use than those with firm belief.
465 This finding aligns with Balami et al., 2020, that knowledge about the efficacy of SP predicts the
466 receipt of the first SP dose. And ultimately, the subsequent IPTp-SP doses during pregnancy (37).
467 Also, pregnant women's awareness of the morbidity caused by malaria predicted higher uptake of
468 at least one SP dose but not optimal doses received. In agreement with the finding, Arnaldo *et al.*,
469 2019 found that a lack of awareness of malaria-associated morbidity reduced the odds of taking
470 SP by pregnant women in Mozambique (38). These findings reiterate the need to utilise social and
471 behaviour change communication strategies to drive IPTp-SP uptake at the community level.
472 Meanwhile, there was no significant association among women who subscribed to health insurance
473 and IPTp-SP uptake during pregnancy. In contrast, Darteh *et al.*, 2020 found an increased IPTp-
474 SP uptake among women with health insurance coverage in Ghana (13). The difference in findings
475 may be because only 2% of study participants were covered by health insurance in Nigeria
476 compared to the study in Ghana where about 48% of study participants were covered by health
477 insurance (13).

478 The major strength of this study was using a nationally representative sample to establish the
479 factors related to IPTp-SP uptake. Next, the sample used was considerably large (n=12,742).
480 Therefore, the findings may be generalisable to Nigerian women with live births on the factors that
481 may influence the effective delivery of IPTp-SP during pregnancy. However, it is essential to note
482 the following limitations in considering the factors associated with IPTp-SP use among women
483 with live births in Nigeria. First, the established factors associated with IPTp-SP use do not imply
484 causality because of the cross-sectional nature of the study design. Secondly, this study could not
485 assess pregnant women's attitudes and healthcare-related constraints concerning IPTp-SP use
486 because the analysis was limited to the variables in the 2018 NDHS questionnaire. Therefore, there
487 is a likelihood that women who attended at least four ANC visits during pregnancy did not receive
488 IPTp-SP because of a stock-out of the drug. Third, excluding women who had stillbirths may have
489 resulted in selection bias. The exclusion might have reduced the estimated effect of each possible
490 factor on the uptake of IPTp-SP (39). Fourth, as a self-reported survey, the study is liable to social
491 desirability bias as the women's self-reported responses might not reflect the reality of the issues.
492 Lastly, recall bias is an inherent limitation of survey designs resulting in varying degrees of
493 accuracy in their previous experiences. However, some recall biases were minimised by including
494 only women with live births during or two years before the Nigeria Demographic Health Survey
495 in 2018.

496 **Conclusion**

497 There is low uptake of at least one IPTp-SP dose and even lower uptake of three or more doses by
498 pregnant women in Nigeria. This low uptake of IPTp-SP was associated with several maternal
499 characteristics, age group, education, antenatal care attendance, household wealth index and trust
500 in the efficacy and safety of SP. Therefore, there is a need for context-specific strategies such as

501 targeted mass sensitisation and community awareness to increase the coverage of IPTp-SP uptake
502 among vulnerable women. In addition, future research should explore the drivers of region-specific
503 low uptake of optimal doses among pregnant women, especially in South-West Nigeria. IPTp-SP
504 uptake remains suboptimal despite a relatively high antenatal care attendance among pregnant
505 women in Nigeria. This situation calls for urgent action to deploy region-specific strategies to
506 mitigate the bottlenecks (such as drug stock-out and non-compliance to the guidelines) at the
507 healthcare facilities that hinder the delivery of IPTp-SP via ANC clinics in Nigeria. Also, pregnant
508 women's belief in the effectiveness of IPTp-SP influences their decision to initiate antimalarial
509 treatment. Therefore, future research should examine the effectiveness of social-behavioural
510 change communication strategies in driving uptake of three or more IPTp-SP doses during
511 pregnancy in Nigeria.

512

513

514

515

516

517

518

519 **Acknowledgement**

520 We are grateful to Measure DHS for the permission and for providing me with the dataset for this
521 study. The authors also would like to thank the University of the Witwatersrand Human Research
522 Ethics Committee (Medical) for the ethical approval.

523 **Authors contribution**

524 **Conceptualisation:** Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura, Latifat Ibisomi

525 **Data curation:** Godwin Okeke Kalu

526 **Formal analysis:** Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura

527 **Methodology:** Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura, Latifat Ibisomi,
528 Tobias Chirwa

529 **Funding Acquisition:** Latifat Ibisomi, Tobias Chirwa

530 **Project administration:** Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura

531 **Supervision:** Joel Msafiri Francis, Juliana Kagura

532 **Validation:** Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura

533 **Visualisation:** Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura

534 **Writing- original draft preparation:** Godwin Okeke Kalu

535 **Writing- review and editing:** Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura, Latifat
536 Ibisomi, Tobias Chirwa

537

538 **Funding**

539 TDR supported this research work as part of the Special Programme for Research and Training in
540 Tropical Diseases (TDR). TDR is hosted by the World Health Organization and co-sponsored by
541 UNICEF, UNDP, the World Bank and WHO. The TDR grant number: B40299. The funders did

542 not play a role in the study design, data collection and analysis, decision to publish or preparation
543 of the manuscript.

544 **Competing interests**

545 The authors have declared no competing interests exist.

546

547 **Availability of data and materials**

548 The dataset for the study was obtained with permission from the Demographic and Health Surveys
549 (DHS) Program. The dataset are publicly available and may be requested from the DHS Program
550 office via https://www.dhsprogram.com/data/dataset_admin/. The questionnaire used for the
551 analyses is the women's questionnaire contained within the 2018 NDHS, which can be accessed
552 via <https://www.dhsprogram.com/publications/publication-FR359-DHS-FinalReports.cfm>.

553

554

555

556

557

558

559

560 **References**

- 561 1. World Health Organization. World Malaria Report: 20 years of global progress and
562 challenges. World Health Organization. 2020.
- 563 2. World Health Organization. World malaria report 2019 [Internet]. 2019. Available from:
564 <https://www.who.int/publications/i/item/world-malaria-report-2019>
- 565 3. Rogerson SJ, Desai M, Mayor A, Sicuri E, Taylor SM, van Eijk AM. Burden, pathology,
566 and costs of malaria in pregnancy: new developments for an old problem. Vol. 18, *The*
567 *Lancet Infectious Diseases*. Lancet Publishing Group; 2018. p. e107–18.
- 568 4. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy:
569 pathogenesis and immunity. Vol. 7, *Lancet Infectious Diseases*. Elsevier; 2007. p. 105–17.
- 570 5. WHO Global Malaria Programme. New WHO recommendations for IPTp-SP [Internet].
571 2013 [cited 2021 Feb 8]. Available from:
572 http://whqlibdoc.who.int/publications/2010/9789241599412_eng.pdf
- 573 6. Kayentao K, Garner P, Van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent
574 preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of
575 sulfadoxine-pyrimethamine and risk of low birth weight in Africa: Systematic review and
576 meta-analysis. Vol. 309, *JAMA - Journal of the American Medical Association*. JAMA;
577 2013. p. 594–604.
- 578 7. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Stillbirths:
579 Rates, risk factors, and acceleration towards 2030. Vol. 387, *The Lancet*. 2016. p. 587–
580 603.
- 581 8. Hill J, Hoyt J, van Eijk AM, D’Mello-Guyett L, ter Kuile FO, Steketee R, et al. Factors
582 Affecting the Delivery, Access, and Use of Interventions to Prevent Malaria in Pregnancy
583 in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Noor AM, editor. *PLoS*
584 *Medicine*. 2013 Jul 23;10(7):e1001488.
- 585 9. Balami AD, Said SM, Zulkefli NAM, Bachok N, Audu B. Effects of a health educational
586 intervention on malaria knowledge, motivation, and behavioural skills: A randomized
587 controlled trial PACTR201610001823405 PACTR. *Malaria Journal*. 2019;18(1):1–14.
- 588 10. Pons-Duran C, Llach M, Sacoor C, Sanz S, Macete E, Arikpo I, et al. Coverage of
589 intermittent preventive treatment of malaria in pregnancy in four sub-Saharan countries:
590 findings from household surveys. *International Journal of Epidemiology*. 2020;1–10.
- 591 11. Muhammad FM, Majdzadeh R, Nedjat S, Sajadi HS, Parsaeian M. Socioeconomic
592 inequality in intermittent preventive treatment using Sulphadoxine pyrimethamine among
593 pregnant women in Nigeria. *BMC Public Health*. 2020;20(1):1–9.
- 594 12. Yaya S, Uthman OA, Amouzou A, Bishwajit G. Use of intermittent preventive treatment
595 among pregnant women in sub-Saharan Africa: Evidence from malaria indicator surveys.
596 *Tropical Medicine and Infectious Disease*. 2018;3(1).
- 597 13. Darteh EKM, Buabeng I, Akuamoah-Boateng C. Uptake of intermittent preventive

- 598 treatment in pregnancy for malaria: further analysis of the 2016 Ghana Malaria Indicator
599 Survey. *Journal of Public Health (Germany)*. 2020;
- 600 14. Olukoya OO, Adebisi OA. Missed Opportunities for Intermittent Preventive Treatment
601 for Malaria in Pregnancy in Nigeria: Evidence From Demographic and Health Survey in
602 Nigeria 2013. *Annals of Ibadan postgraduate medicine*. 2017;15(2):88–95.
- 603 15. Mchwampaka WM, Tarimo D, Chacky F, Mohamed A, Kishimba R, Samwel A. Factors
604 affecting uptake of ≥ 3 doses of Sulfadoxine-Pyrimethamine for malaria prevention in
605 pregnancy in selected health facilities, Arusha region, Tanzania. *BMC Pregnancy and
606 Childbirth*. 2019 Nov 27;19(1).
- 607 16. Exavery A, Mbaruku G, Mbuyita S, Makemba A, Kinyonge IP, Kweka H. Factors
608 affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent
609 preventive treatment of malaria in pregnancy in six districts of Tanzania. *Malaria Journal*.
610 2014 Jan 14;13(1).
- 611 17. Ndu A, Mbachu C, Anitube O, Ezeoke U. Inequities in the use of sulphadoxine-
612 pyrimethamine for malaria prophylaxis during pregnancy in Nigeria. *Malawi Medical
613 Journal*. 2020;32(1):45–51.
- 614 18. Rassi C, Graham K, King R, Ssekitooleko J, Mufubenga P, Gudoi SS. Assessing demand-
615 side barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a
616 qualitative study in two regions of Uganda. *Malaria Journal*. 2016;15(1):1–14.
- 617 19. NPC, ICF. The Federal Republic of Nigeria Nigeria Demographic and Health Survey
618 2018 National Population Commission Abuja, Nigeria. 2019.
- 619 20. Chukwu C, Onuoha H, Adline Katty Okorafor K, Ojomo O, Mokuolu OA, Ekholuenetale
620 MI. Geopolitical zones differentials in intermittent preventive treatment in pregnancy
621 (IPTp) and long lasting insecticidal nets (LLIN) utilization in Nigeria. 2021;
- 622 21. Oppong FB, Gyaase S, Zandoh C, Nettey OEA, Amenga-Etego S, Anane EA, et al.
623 Intermittent preventive treatment of pregnant women in Kintampo area of Ghana with
624 sulphadoxine-pyrimethamine (SP): Trends spanning 2011 and 2015. *BMJ Open*.
625 2019;9(6).
- 626 22. Okafor I, Ezekude C, Oluwole E, Onigbogi O. Malaria in pregnancy: A community-based
627 study on the knowledge, perception, and prevention among Nigerian women. *Journal of
628 Family Medicine and Primary Care*. 2019;8(4):1359.
- 629 23. StataCorp. 2019. Stata Statistical Software: Release 16. College Station TSL. Stata |
630 StataCorp LLC [Internet]. [cited 2021 Apr 12]. Available from:
631 <https://www.stata.com/company/>
- 632 24. Fidock DA. Eliminating malaria [Internet]. Vol. 340, *Science*. 2013 [cited 2021 Nov 22].
633 p. 1531–3. Available from: <http://www.who.int>
- 634 25. Okethwangu D, Opigo J, Atugonza S, Kizza CT, Nabatanzi M, Biribawa C, et al. Factors
635 associated with uptake of optimal doses of intermittent preventive treatment for malaria
636 among pregnant women in Uganda: Analysis of data from the Uganda Demographic and
637 Health Survey, 2016. *Malaria Journal*. 2019 Jul 26;18(1):250.

- 638 26. Azizi SC. Uptake of intermittent preventive treatment for malaria during pregnancy with
639 Sulphadoxine-Pyrimethamine in Malawi after adoption of updated World Health
640 Organization policy: An analysis of demographic and health survey 2015-2016. *BMC*
641 *Public Health*. 2020 Mar 16;20(1).
- 642 27. Olugbade OT, Ilesanmi OS, Gubio AB, Ajayi I, Nguku PM, Ajumobi O. Socio-
643 demographic and regional disparities in utilization of intermittent preventive treatment for
644 malaria in pregnancy - Nigeria demographic health survey 2013. *The Pan African medical*
645 *journal*. 2019;32:13.
- 646 28. Kibusi SM, Kimunai E, Hines CS. Predictors for uptake of intermittent preventive
647 treatment of malaria in pregnancy (IPTp) in Tanzania. 2015;
- 648 29. Wanzira H, Katamba H, Okullo AE, Rubahika D. The challenge of using intermittent
649 preventive therapy with sulfadoxine/pyrimethamine among pregnant women in Uganda.
650 *Malaria Journal*. 2016;15(1):1–7.
- 651 30. Sanadgol A, Doshmangir L, Majdzadeh R, Gordeev VS. Engagement of non-
652 governmental organisations in moving towards universal health coverage: a scoping
653 review. *Globalization and Health*. 2021 Dec 1;17(1).
- 654 31. Akpa CO, Akinyemi JO, Umeokonkwo CD, Bamgboye EA, Dahiru T, Adebowale AS, et
655 al. Uptake of intermittent preventive treatment for malaria in pregnancy among women in
656 selected communities of Ebonyi State, Nigeria. *BMC Pregnancy and Childbirth*.
657 2019;19(1):1–7.
- 658 32. Oguntunde O, Nyenwa J, Yusuf FM, Dauda DS, Salihu A, Sinai I. The experience of men
659 who participated in interventions to improve demand for and utilization of maternal and
660 child health services in northern Nigeria: A qualitative comparative study. *Reproductive*
661 *Health*. 2019;16(1):1–9.
- 662 33. Nkoka O, Chuang TW, Chen YH. Association between timing and number of antenatal
663 care visits on uptake of intermittent preventive treatment for malaria during pregnancy
664 among Malawian women. *Malaria Journal*. 2018;17(1):1–11.
- 665 34. Mchwampaka WM, Tarimo D, Chacky F, Mohamed A, Kishimba R, Samwel A. Factors
666 affecting uptake of ≥ 3 doses of Sulfadoxine-Pyrimethamine for malaria prevention in
667 pregnancy in selected health facilities, Arusha region, Tanzania. *BMC Pregnancy and*
668 *Childbirth*. 2019;19(1):1–8.
- 669 35. Okello G, Gerrets R, Zakayo S, Molyneux S, Jones C. "Every day they keep adding new
670 tools but they don't take any away": Producing indicators for intermittent preventive
671 treatment for malaria in pregnancy (IPTp) from routine data in Kenya. *PLoS ONE*.
672 2018;13(1):1–14.
- 673 36. Hurley EA, Harvey SA, Rao N, Diarra NH, Klein MC, Diop SI, et al. Underreporting and
674 missed opportunities for uptake of intermittent preventative treatment of malaria in
675 pregnancy (IPTp) in Mali. *PLoS ONE*. 2016;11(8):1–17.
- 676 37. Balami AD, Md. Said S, Nor NA, Bachok N, Audu B. Determinants of uptake of first
677 dose of intermittent preventive treatment among pregnant women in a secondary health

678 Centre in Maiduguri, Nigeria. BMC Pregnancy and Childbirth. 2020;20(1):1–9.

679 38. Arnaldo P, Cambe MI, Magaço A, Chicumbe S, Rovira-Vallbona E, Rosanas-Urgell A, et
680 al. Access to and use of preventive intermittent treatment for Malaria during pregnancy: A
681 qualitative study in the Chókwè district, Southern Mozambique. PLoS ONE.
682 2019;14(1):1–12.

683 39. Moore KA, Simpson JA, Scoullar MJL, McGready R, Fowkes FJI. Quantification of the
684 association between malaria in pregnancy and stillbirth: a systematic review and meta-
685 analysis. The Lancet Global Health. 2017 Nov 1;5(11):e1101–12.

686
687
688
689

690 Supporting information

691 **S1 Table. Interaction term between Household wealth Index and Spouse’s Educational level.**

692 This is the extension of Table 4 with interaction term


693 **S2 Table. Full multivariable logistic regression for the uptake of at least one IPTp-SP dose**
694 **(Table 4).** This is the STATA output for the final model (Table 4)

695 **S3 Table. Full multivariable logistic regression for uptake of at least three IPTp-SP doses.**
696 This is the STATA output for the final model (Table 5)

697 **S4 Table. The model without interaction term for the uptake of at least one IPTp-SP dose.**
698 This is the initial model without the interaction for factors associated with at least one SP dose.

699 **S5 Table. The model without interaction term for the uptake of at least one IPTp-SP dose.**
700 This is the STATA output for the initial model without interaction term

701
702
703
704
705



Figure